[go: up one dir, main page]

WO1997032591A1 - Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance - Google Patents

Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance Download PDF

Info

Publication number
WO1997032591A1
WO1997032591A1 PCT/US1997/004810 US9704810W WO9732591A1 WO 1997032591 A1 WO1997032591 A1 WO 1997032591A1 US 9704810 W US9704810 W US 9704810W WO 9732591 A1 WO9732591 A1 WO 9732591A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone
bfgf
composition
growth
hyaluronic acid
Prior art date
Application number
PCT/US1997/004810
Other languages
English (en)
Inventor
Michael Radomsky
Original Assignee
Orquest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orquest, Inc. filed Critical Orquest, Inc.
Priority to JP53207097A priority Critical patent/JP2002504083A/ja
Priority to AU25449/97A priority patent/AU729086C/en
Priority to EP97916976A priority patent/EP0910389A4/fr
Priority to NZ331238A priority patent/NZ331238A/xx
Priority to CA2246747A priority patent/CA2246747C/fr
Publication of WO1997032591A1 publication Critical patent/WO1997032591A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Hyaluronic acid is a naturally-occurring polysaccharide containing alternating N-acetyl-D- glucosamine and D-glucuronic acid monosaccharide units linked with beta 1-4 bonds and the disaccharide units linked with beta 1-3 glycoside bonds. It occurs usually as the sodium salt and has a molecular weight range of about 50,000 to 8xl0 6 .
  • the present invention provides a bone growth- promoting composition comprising hyaluronic acid and a growth factor such that the composition has a viscosity and biodegradability sufficient to persist at the site of desired bone growth for a period of time sufficient to promote bone growth.
  • Compositions comprising hyaluronic acid and a growth factor are provided which have the requisite viscosity and biodegradability.
  • hyaluronic acid means hyaluronic acid and its salts such as the sodium, potassium, magnesium, calcium, and the like, salts.
  • growth factors it is meant those factors, proteinaceous or otherwise, which are found to play a role in the induction or conduction of growth of bone, ligaments, cartilage or other tissues associated with bone or joints.
  • these growth factors include bFGF, aFGF, EGF (epidermal growth factor) , PDGF (platele - derived growth factor) , IGF (insulin-like growth factor) , TGF- ⁇ I through III, including the TGF-jS superfamily (BMP-1 through 12, GDF 1 through 12, dpp, 60A, BIP, OF) .
  • FIG. 1 is a graphical representation of experimental data set forth in example 1 below;
  • FIG. IA shows the bone thickness formed as a function of bFGF dosage;
  • FIG. IB shows bone thickness formation as a function of hyaluronic acid concentration;
  • FIG. 2 is a graphical representation of the experimental data set forth in Example 2 below.
  • FIG. 3 is a graphical representation of the load at failure of healing rabbit fibula after 23 and 30 days following treatment according to Example 3.
  • FIG. 4 is a graphical representation of the energy to failure (in pounds) of healing rabbit fibula after 23 and 30 days following treatment according to Example 3.
  • FIG. 5 is a graphical representation of the bone thickness data in rats following treatment according to Example 4.
  • the HA is preferably uncrosslinked having a molecular weight of 500,000 and above, typically in the range of 10 4 to 10 7 .
  • the bone growth-promoting compositions will typically contain from about 0.1 up to 4 percent by weight of uncrosslinked HA in an aqueous solution which also contains other solution excipients such as buffer salts, sugars, anti-oxidants and preservatives to maintain the bio-activity of the growth factor and proper pH of the composition.
  • a composition containing from about 0.1 to 2 percent by weight of uncrosslinked HA is preferred.
  • a typical pH of the solution will be in the range of 4 to 9, preferably about 6.0 ⁇ 1.0 and most preferably about 5.0.
  • the growth factor will typically be present in the solution in a concentration range of about 10 ⁇ 6 to 100 mg/ml of solution, particularly in the case of bFGF preferably about 0.1 to 20 mg/ml.
  • concentration will be dependent upon the particular bone site and application, as well as the volume of the injection and specific activity of the growth factor. It is important for the solution used to promote the growth to have a viscosity which allows it to be injectable through a syringe or catheter, but not to be prematurely diluted by the body fluids before the bone promoting effect can be achieved.
  • the viscosity of the composition is within a range of 10 to 10 6 cP and, in the case of bFGF-containing compositions, preferably about 75,000 cP.
  • composition it is also important for the composition to have a biodegradability which is sufficient to allow it to remain in place at the site of desired bone growth to effect the bone growth-promoting activity.
  • the composition must usually persist at the site of desired bone growth for a period from about three (3) to about thirty (30) days, typically from three (3) to about fourteen (14) days. If the composition is dispersed prematurely, the desired bone growth-promotion effect either will not occur or the formed bone will not have the desired strength.
  • composition persists at the site of desired bone growth for an excessive period, its presence at the bone site may inhibit the natural development of the bone, sometimes resulting in no bone formation at all.
  • compositions are typically formed as solutions by mixing the HA and growth factor in appropriate amounts of excipients such as sodium citrate, EDTA and sucrose so that the HA and growth factor remain in solution at the desired concentration and the solution exhibits the appropriate viscosity and biodegradability.
  • excipients such as sodium citrate, EDTA and sucrose
  • the solution may be applied to the site of desired bone growth in any convenient manner, typically by introduction through a syringe or catheter.
  • a bone growth composition of the present invention may be desirable to accelerate wound healing, prevent further tissue damage occurring subsequent to injury, avoid treatments that compromise the natural healing process and create optimal physical and biological conditions for healing.
  • Sites of desired bone growth include tibia/fibula fractures; femur/humerus fractures; forearm fractures; posteriorly displaced distal radius (Colles) fracture; stress fractures including sports fractures associated with shin splints and foot injuries; vertebral compression fractures, rib fractures and clavicular fractures.
  • Sites of desired bone growth also include pathological bone defects associated with osteoporosis, osteomalacia, hyperparathyroidism, renal osteodystrophy, and primary and metastatic cancer of the bone.
  • Example 1 Sodium hyaluronate (Genzyme, MW 2xl0 6 , sterile, viscosity in 1% solution of 6500 cP) , bFGF (Scios-Nova, 4.3 mg/ml solution (pH 5) in 9% sucrose, 20 mM sodium citrate and 1 mM EDTA) were mixed.
  • the formulations were formed by mixing sterile-filtered solutions of bFGF and other excipients (sodium citrate, water, etc.) with the appropriate amount of solid, sterile HA. The HA was dispersed quickly by repeated back and forth syringing to prevent the formation of large aggregates of particles.
  • Formulations were prepared aseptically and administered in prefilled 1 ml plastic syringes with 21G needles into male Sprague-Dawley rats (8-9 weeks old, 160-180 grams) , which were anesthetized with acepromazine, xylazine and ke amine . A 5-10 millimeter incision was made laterally in the skin at the back of the neck to locate the intersection of the sagittal and lambdoid sutures. Fifty microliters of the test formulation was injected with a 21G needle between the periosteum and parietal bone. The animals were euthanized 14 days following treatment.
  • Tissues for histological analysis were fixed in 10% neutral buffered formalin. Tissues were decalcified for at least 2 hours in formic acid (RapidBone Decal) with constant, gentle agitation. Samples were dehydrated and infiltrated with paraffin. Specimens were then embedded in a cross-sectional plane and sectioned at 5 ⁇ m. Sections were stained with hematoxylin and eosin for histological analysis. New bone formation was scored on a scale of 0 to 4 as shown in Table 1.
  • Table 1 Qualitative description of new, woven bone formation on parietal bone following subperiostal injection.
  • the total thickness of the parietal bone was measured similar to the method of Noda et al . , Endocrinology, 124:2991-4, 1989.
  • a photograph of each histology section was taken 2 to 3 mm lateral to the sagittal suture (the approximate midpoint between the sagittal suture and the edge of the section) .
  • Three bone thickness measurements of total bone were taken at the left, middle, and right side of the photograph and scaled to determine total bone thickness. Both dense cortical bone and new, woven bone were included in the measurement.
  • Table 3 shows the total bone thickness of the rat calvaria after receiving different formulations by subperiosteal injection. All formulations containing bFGF and HA exhibited new bone formation. The first two entries in table 3 represent replicate experiments. Replicate groups of animals receiving 100 ⁇ g bFGF in a 2% HA gel had a total parietal bone thickness of 0.49+0.10 mm in the first study and 0.59 ⁇ 0.12 mm in the second study, a 17% difference. However, the total bone thickness of both groups was qualitatively and quantitatively significantly different than control. All formulations containing 100 ⁇ g of bFGF and HA had at least a 61% increase in new bone formation compared to animals receiving no treatment. FIG.
  • IA and IB show the effect of bFGF and HA concentration on total bone thickness.
  • the dose of bFGF increase from 10 to 100 ⁇ g, the total bone thickness increases 20% from 0.45 to 0.54 mm.
  • concentration of HA increases, an increase in total bone formation is seen until a maximum increase in bone formation is observed near 0.5% HA; increasing the concentration of HA above 0.5% does not result in an additional increase in new bone formation elicited by bFGF in this model (FIG. IB) .
  • Table 3 The total bone thickness of a section of the rat calvaria 2 mm anterior of the lambda and 2 to 3 mm lateral to the parietal suture 14 days following treatmen . Bone thickness is the average of 3 measurements per animal. n is the number of replicate animals, and the percent increase represents the fractional increase over growth control .
  • Example 2 The tests described in Example 1 were conducted using 8 different formulations. The bFGF was used in combination with hyaluronic acid as compared to 7 other compositions wherein bFGF was used with other carriers or the carriers were used alone as placebos. The results are shown below and are summarized in FIG. 2 and Table 4.
  • Table 4 The total number of animals with a bone formation score
  • Example 3 Formulations of sodium hyaluronate (2%) and bFGF (4 mg/ml) were prepared as in Example 1 for administration to a fracture site in rabbits. A formulation was also prepared containing 4 mg/ml bFGF, 6 mg/ml rabbit fibrinogen, 0.2 mg/ml aprotinin, and other excipients to maintain pH and stability. This fibrinogen formulation was similar to a previously published composition used for fracture repair 1 . A 1 mm cut in the fibula mid-diaphysis was surgically created in New
  • FIG. 3 illustrates the load at failure for untreated, HA/bFGF treated, and fibrinogen/bFGF treated fibulae.
  • the HA/bFGF treated fibulae were 53% stronger than untreated control, while the fibrin/bFGF treated fibulae were 30% stronger than untreated control .
  • Figure 4 shows the energy to failure for all three treatment groups. By this measurement, the HA/bFGF treated fibulae were 43% stronger than untreated control, while the fibrin/bFGF treated fibulae were 3% weaker than untreated control.
  • Example 4 The method in Example 1 was used to compare total bone formation of the HA/bFGF formulation in Example 1, the fibrin/bFGF formulation in Example 3, and a bFGF in an aqueous sucrose/citrate buffer formulation. 100 ⁇ g of bFGF in 50 ⁇ L each formulation was administered by subperiosteal injection, and animals were sacrificed 7 and 14 days post-administration. In addition, animals receiving no treatment were used as controls.
  • Figure 5 shows the quantitative results of the bone thickness measurement .
  • the thickness 7 days after treatment is 95% thicker in the animals administered 100 ⁇ g of bFGF in a 2% HA gel than in animal receiving no treatment (i.e. control) .
  • the other bFGF treated groups showed a 86 and 55% increase in bone formation by treatment with bFGF in a fibrin gel and bFGF in an aqueous citrate buffer, respectively.
  • Example 5 The effect of the molecular weight of hyaluronic acid in basic fibroblast growth factor (bFGF) formulations on intramembranous bone formation was examined by subperiosteal injection to the rat parietal bone.
  • bFGF basic fibroblast growth factor
  • the HA with a molecular weight of 760 to 2300 KDa was used to prepare formulations.
  • the BFGF was provided (Scios-Nova) as a frozen solution (4.3 mg/ml) in 9% sucrose, 20 mM sodium citrate, and 1 mM EDTA adjusted to pH 5.0.
  • Other reagents (sucrose, sodium citrate, EDTA) were purchased from Sigma.
  • Formulations were prepared by mixing a sterile filtered solution of bFGF (2 mg/ml) with the appropriate amount of HA (20 mg/ml) .
  • the solution and carrier initially were in separate syringes connected by a stopcock.
  • the formulation was mixed by repeated back and forth syringing.
  • Formulations were prepared aseptically and administered in prefilled 1 ml plastic syringes with a 21G needle.
  • Male Sprague-Dawley rats (8-9 weeks old, 160-180 g) were anesthetized with a mixture of acepromazine, xylazine, and keta ine.
  • a small incision (5-10 mm) was made laterally in the skin at the back of the neck.
  • the intersection of the sagittal and lambdoid sutures was located, and 50 ⁇ L of each formulation was injected with 21 G needle on the left side between the periosteum and parietal bone.
  • Fourteen days following treatment animals were euthanized by C0 2 asphyxiation.
  • Tissues for histological analysis were fixed in 10% neutral buffered formalin. Tissues were decalcified for at least 2 hours in formic acid (RapidBone Decal) with constant, gentle agitation. Samples were dehydrated and infiltrated with paraffin. Specimens were then embedded in a cross-sectional plane and sectioned at 5 ⁇ M. Sections were stained with hematoxylin and eosin for histological analysis. New bone formation was scored on a scale of 0-4.
  • a score of 0 represented no new woven bone; a score of 1 represented trace or patchy areas of woven bone; a score of 2 represented larger areas of patchy bone formation; a score of 3 represented thin, continuous woven bone ( ⁇ 50% of original parietal bone) and a score of 4 represented thick, continuous woven bone (>50% of original parietal bone) .
  • Bone Thickness Measurement The total thickness of the parietal bone was determined at the site of injection. A photograph of each histology section was taken 2 to 3 mm lateral to the sagittal suture (the approximate midpoint between the sagittal suture and the edge of the section) . Three bone thickness measurements of total bone were taken at the left, middle, and right side of the photograph and scaled to determine total bone thickness. Both dense cortical bone and new, woven bone were included in the measurement .
  • the HA gel treated animals showed no or very little new bone formation, and most animals received a bone formation score of 0 (26/30) .
  • Three of 30 animals had a bone formation score of 1 while a single animal had a bone formation of 3.
  • the new bone formation may be a result of elevation of the periosteum during the surgical procedure. No abnormalities are observed in any part of the tissue, and there is no indication of antigenic potential in any of the HAs examined. Animals receiving no surgery and no treatment showed no new bone formation and all six animals received a bone formation score of zero.
  • This group was very similar to the groups receiving HA gel, except that no new bone formed as a result of elevation of the periosteum.
  • the specimens consisted of mature bone in which normal osteocytes are present in lacunae, and marrow spaces were seen. Small amounts of fine fibrous tissue are present superficially to the bone tissue in all sections.
  • FGF treated groups had a 68-100% increase in bone thickness over the growth control.
  • the animals treated with bFGF in a gel formed from Lifecore' s highest molecular weight HA available had the largest increase in bone thickness (100%) .
  • the molecular weight of HA increased, the amount of new bone formed also increased. This increase in bone formation could be due to the increase in viscosity of the formulation. As the viscosity increased, it became a larger diffusional barrier for the FGF maintaining it at the site locally for a longer period. The longer residence time of HA then results in more bone formation.
  • Example 6 This Example addresses the local distribution and persistence of hyaluronic acid following subperiosteal injection of an HA + bFGF gel.
  • This study examined the proliferation of the periosteum, new bone formation, and the local distribution and persistence of hyaluronic acid (HA) following subperiosteal injection of an HA gel containing basic fibroblast growth factor (bFGF) .
  • the periosteal thickness at 3 days and bone thickness at 10 days was determined by histologic evaluation.
  • HA Sodium hyaluronate
  • Lifecore Biomedical Chocore Biomedical (Chaska, MN, 1300 kDa) .
  • bFGF was provided by Scios-Nova as a frozen solution (4.3 mg/ml) in 9% sucrose, 20 mM sodium citrate, and 1 mM EDTA adjusted to pH 5.
  • Formulation buffer reagents (sucrose, sodium citrate, EDTA, BSA) were purchased from Sigma.
  • Adipic dihydrazide (AD) and l-ethyl-3[3- (dimethylamino)propyl] carbodiimide (EDC) were purchased from Aldrich.
  • SNB Sulfo-NHS-Biotin
  • HABA 2- (4' hydroxyphenylazo) benzoic acid
  • DAB 3,3' diamino benzidine tetrahydrochloride
  • Av- HRP avidin-horseradish peroxidase conjugate
  • HA-Biotin (HA-Bi) conjugate was prepared by a two step reaction. Hydrazido-HA was synthesized followed by preparation of HA-Bi according to the method of
  • Hydrazido-HA was prepared by dissolving 200 mg of HA in 50 ml of water.
  • AD 3.5 g
  • EDC 382 mg
  • the pH was monitored periodically and maintained at 4.75 by the addition of 0.1 N HCl.
  • the reaction was stopped after 4 hours (at this point no further increase in pH was detected) by neutralization to pH 7 with 1 N NaOH. This product was dialyzed for 72 hrs
  • the HA-Bi conjugate was prepared by dissolving 15 mg of Hydrazido-HA in 1.5 ml of 0.1 M NaHC03.
  • the SNB 50 mg was added to begin the reaction.
  • the solution was stirred with a small magnetic stir bar for 20 hours at room temperature.
  • the solution was dialyzed for 72 hours and then lyophilized for 48 hours.
  • the degree of substitution was determined by a displacement assay according to the manufacturer's protocol (Pierce) . Briefly, 900 ⁇ L of avidin-HABA reagent was placed in a 1 ml cuvette.
  • the absorbance at 500 nm was compared to the absorbance of a solution of 900 ⁇ L of Avidin-HABA plus 100 ⁇ L of a 1 mg/ml HA-Biotin solution.
  • the average degree of substitution was 30 moles of repeating disaccharide unit per mole of biotin.
  • Formulations were prepared by mixing a sterile- filtered solution of bFGF with solid HA as described in Table 5. The formulation was mixed by repeated back and forth motion of two syringes connected by a stopcock. Formulations were prepared aseptically and administered in prefilled 1 ml plastic syringes with a 21 G needle.
  • Tissues for histological evaluation were fixed in 10% neutral buffered formalin then decalcified in a 13 to 15% solution of EDTA with constant, gentle agitation. Samples were dehydrated and infiltrated with paraffin. Specimens were then embedded in a cross-sectional plane and sectioned at 4 ⁇ m. Two sections were prepared for each specimen and were stained with hematoxylin and eosin (H&E) or stained for HA with Bi:Av-HRP histochemistry by the following method. Tissue sections were incubated for 30 min in blocker solution (l%BSA/0.05% Tween in PBS) followed by a 60 min incubation in detecting conjugate solution
  • the total thickness of the periosteum and parietal bone was determined at the site of injection.
  • a photograph of each histology section was taken 2 to 3 mm lateral to the sagittal suture (the approximate midpoint between the sagittal suture and the edge of the section) .
  • Three thickness measurements were taken at the left, middle, and right side of the photograph and scaled to determine total bone thickness or periosteum thickness.
  • Tissue with similar staining characteristics and cell morphology to normal periosteum was included in the periosteum thickness. Both dense cortical bone and new, woven bone were included in the bone thickness measurement .
  • HA-Bi was detected in the tissues immediately adjacent to the thickened periosteum at 3 days and the newly formed bone at 10 days.
  • HA a distinct mass of HA was present above the periosteum.
  • periosteum elevated from the lamellar bone from the surgical trauma.
  • fibrous tissue In the area stained for HA, there was a localized area of fibrous tissue and a non-specific cellular infiltrate in which lymphocytes and degenerating cells were evident.
  • the surrounding tissue consisted of fine fibrous tissue.
  • the HA-Bi treated animals showed normal lamellar bone with an area of non-specific fibrous tissue resembling granulation tissue above it. This area contained lymphocytes, fine blood vessels, fat cells and a few fragments of unstained material .
  • the brownish- black peroxidase stain was within the dense fibrous tissue superficial to the calvarium on the left side.
  • the HA was distributed non-specifically within the fibrous tissue.
  • periosteum in HA-Bi + FGF treated animals was 403% greater than animals treated only with HA-Bi gel.
  • a mass of vascularized, exuberant fibrous tissue was present above the thickened periosteum.
  • fat cells were present and a non-specific inflammatory cell infiltrate containing some polymorphonuclear leukocytes, histocytes and plasma cells were present.
  • the residual HA extended across the midline suture and appeared to be undergoing encapsulation.
  • These samples showed a concentration of brownish-black stained material (i.e. HA) mainly concentrated within the confines of the encapsulated tissue. More of this material appeared to be non- specifically retained within a fibrous network and some appeared to be non-specifically accumulated within the cytoplasm of local histocytes.
  • HA-Bi + bFGF administration at 10 days
  • the injection site showed that the preexisting calvarial lamellar bone was covered by a thick layer of maturing woven bone which was normal in structure and staining qualities.
  • the total bone thickness was 70% greater in animals treated with HA-Bi + FGF than in animals receiving HA-Bi gel. This new bone typically extended just beyond the midline suture onto the right side of the calvarium.
  • DAB staining for HA was seen in the superficial layers of the fibrous tissue proliferation surrounding the newly formed woven bone.
  • the peroxidase staining indicated that the HA was typically present in tissues adjacent to newly formed bone. Above the woven bone a fibro-periosteal layer was present. Superficial to this there was an extensive area of fine fibrous tissue which was vascularized and contained adipose cells. Some lymphocytes, plasma cells, and histocytes were also present in this well developed area which was limited by a thin fibrous tissue layer.
  • HA + bFGF gel by subperiosteal injection had a significant effect on the proliferation of the periosteum and active bone formation.
  • the periosteum was nearly 5 fold thicker than control.
  • 10 days following administration the parietal bone thickness was 70% greater than control in HA/bFGF treated rats.
  • the HA carrier in the formulations examined here directs the formation of new bone by placement of the material; HA is seen in areas of active bone formation. Following injection of HA + bFGF, the HA provides a reservoir of bFGF adjacent to the site of new bone formation.
  • HA In addition to providing site directed release of bFGF, HA has biological properties that appear to support an environment to promote bone formation. HA may have a synergistic effect with FGF.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition favorisant la croissance osseuse, comprenant un acide hyaluronique et un facteur de croissance. Ladite composition présente une viscosité et une biodégradabilité suffisantes pour persister sur le site sur lequel on désire induire la croissance osseuse, pendant suffisamment de temps pour favoriser la croissance osseuse, On utilise de préférence de l'acide hyaluronique dans la composition, à raison de 0,1 à 4 % en poids, et le facteur de croissance préféré est bFGF, en concentration d'environ 10-6 à 100 mg/ml.
PCT/US1997/004810 1996-03-05 1997-03-05 Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance WO1997032591A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP53207097A JP2002504083A (ja) 1996-03-05 1997-03-05 ヒアルロン酸および増殖因子による骨の増殖を促進する方法
AU25449/97A AU729086C (en) 1996-03-05 1997-03-05 Method of promoting bone growth with hyaluronic acid and growth factors
EP97916976A EP0910389A4 (fr) 1996-03-05 1997-03-05 Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance
NZ331238A NZ331238A (en) 1996-03-05 1997-03-05 Method of promoting bone growth with hyaluronic acid and growth factors (bFGF)
CA2246747A CA2246747C (fr) 1996-03-05 1997-03-05 Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61169096A 1996-03-05 1996-03-05
US08/611,690 1996-03-05

Publications (1)

Publication Number Publication Date
WO1997032591A1 true WO1997032591A1 (fr) 1997-09-12

Family

ID=24450043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004810 WO1997032591A1 (fr) 1996-03-05 1997-03-05 Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance

Country Status (4)

Country Link
EP (1) EP0910389A4 (fr)
JP (1) JP2002504083A (fr)
CN (1) CN1149088C (fr)
WO (1) WO1997032591A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372257B1 (en) 1999-06-29 2002-04-16 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US6699471B2 (en) 1998-12-21 2004-03-02 Fidia Advanced Biopolymers, Srl Injectable hyaluronic acid derivative with pharmaceuticals/cells
US6831178B2 (en) 2000-04-19 2004-12-14 Shionogi & Co., Ltd. Process for preparation of sulfonamide derivatives and crystals thereof
EP1198235A4 (fr) * 1999-07-26 2006-04-05 Depuy Spine Inc Methode d'aide a la croissance osseuse avec de l'acide hyaluronique et des facteurs de croissance
EP1731193A1 (fr) * 2001-07-16 2006-12-13 International Rehabilitative Sciences, Inc. Appareil électromédical utilisé avec des produits biologiques
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
WO2007092829A3 (fr) * 2006-02-07 2007-10-18 Shire Human Genetic Therapies Compositions stabilisees de proteines possedant une fraction de thiol libre
EP0957943B2 (fr) † 1997-02-07 2008-11-26 Stryker Corporation Dispositif osteogeniques sans matrice, implants et methodes d'utilisation associees
US7747332B2 (en) 2000-05-08 2010-06-29 International Rehabilitative Sciences, Inc. Electrical stimulation combined with a biologic to increase osteogenesis
US7875590B2 (en) 2002-05-17 2011-01-25 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US8563040B2 (en) 2002-02-07 2013-10-22 Marfly 2, Lp Compositions and methods for forming and strengthening bone
AU2013224728B2 (en) * 2006-02-07 2016-10-20 Takeda Pharmaceutical Company Limited Stabilized Compositions of Proteins Having a Free Thiol Moiety
WO2017012711A1 (fr) * 2015-07-19 2017-01-26 Tracey Lennemann Nouvelle utilisation d'acide hyaluronique
US9623090B2 (en) 2012-03-02 2017-04-18 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type III gaucher disease
US10041137B2 (en) 2000-08-18 2018-08-07 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US11571466B2 (en) 2009-07-28 2023-02-07 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035816A1 (fr) * 2006-09-21 2008-03-27 Toshiki Oguro Promoteur de régénération des tissus durs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464440A (en) * 1992-01-13 1995-11-07 Lucocer Aktiebolag Porous implant with two sets of pores
US5470829A (en) * 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133755A (en) * 1986-01-28 1992-07-28 Thm Biomedical, Inc. Method and apparatus for diodegradable, osteogenic, bone graft substitute device
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
JPH04282322A (ja) * 1991-03-08 1992-10-07 Denki Kagaku Kogyo Kk 生物活性ペプチド製剤
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
WO1994001483A1 (fr) * 1992-07-02 1994-01-20 Collagen Corporation Conjugues polymeres biocompatibles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470829A (en) * 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
US5464440A (en) * 1992-01-13 1995-11-07 Lucocer Aktiebolag Porous implant with two sets of pores

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0910389A4 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957943B2 (fr) † 1997-02-07 2008-11-26 Stryker Corporation Dispositif osteogeniques sans matrice, implants et methodes d'utilisation associees
JP2009102393A (ja) * 1997-02-07 2009-05-14 Stryker Corp マトリクスを含まない骨形成デバイス、移植片、およびその使用方法
US9254301B2 (en) 1998-03-30 2016-02-09 Marfly2, LP Compositions and methods for forming and strengthening bone
US6699471B2 (en) 1998-12-21 2004-03-02 Fidia Advanced Biopolymers, Srl Injectable hyaluronic acid derivative with pharmaceuticals/cells
US7157080B2 (en) 1998-12-21 2007-01-02 Fidia Advanced Biopolymers, Srl. Injectable hyaluronic acid derivative with pharmaceuticals/cells
EP1203074A4 (fr) * 1999-06-29 2003-09-10 J Alexander Marchosky Compositions et procede de formation et de renforcement des os
US6372257B1 (en) 1999-06-29 2002-04-16 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
EP1198235A4 (fr) * 1999-07-26 2006-04-05 Depuy Spine Inc Methode d'aide a la croissance osseuse avec de l'acide hyaluronique et des facteurs de croissance
JP2009143949A (ja) * 1999-07-26 2009-07-02 Depuy Spine Inc ヒアルロン酸と成長因子を用いた骨成長促進方法
US7608580B2 (en) 1999-10-15 2009-10-27 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
EP2286847A1 (fr) * 1999-10-15 2011-02-23 Genetics Institute, LLC Formulations à base d'acide hyaluronique aux fins de l'administration de proteines osteogenes
US6831178B2 (en) 2000-04-19 2004-12-14 Shionogi & Co., Ltd. Process for preparation of sulfonamide derivatives and crystals thereof
US7747332B2 (en) 2000-05-08 2010-06-29 International Rehabilitative Sciences, Inc. Electrical stimulation combined with a biologic to increase osteogenesis
US10041137B2 (en) 2000-08-18 2018-08-07 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
EP1731193A1 (fr) * 2001-07-16 2006-12-13 International Rehabilitative Sciences, Inc. Appareil électromédical utilisé avec des produits biologiques
US8563040B2 (en) 2002-02-07 2013-10-22 Marfly 2, Lp Compositions and methods for forming and strengthening bone
US7875590B2 (en) 2002-05-17 2011-01-25 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US7833766B2 (en) 2006-02-07 2010-11-16 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
TWI415630B (zh) * 2006-02-07 2013-11-21 Shire Human Genetic Therapies 具有自由硫醇部份的蛋白質的安定化組合物
US8673298B2 (en) 2006-02-07 2014-03-18 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moeity
US9072785B2 (en) 2006-02-07 2015-07-07 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
EP2361613A1 (fr) * 2006-02-07 2011-08-31 Shire Human Genetic Therapies, Inc. Compositions stabilisées de protéines possédant une fraction de thiol libre
AU2013224728B2 (en) * 2006-02-07 2016-10-20 Takeda Pharmaceutical Company Limited Stabilized Compositions of Proteins Having a Free Thiol Moiety
US9694057B2 (en) 2006-02-07 2017-07-04 Shire Huma Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
WO2007092829A3 (fr) * 2006-02-07 2007-10-18 Shire Human Genetic Therapies Compositions stabilisees de proteines possedant une fraction de thiol libre
US11571466B2 (en) 2009-07-28 2023-02-07 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US9623090B2 (en) 2012-03-02 2017-04-18 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type III gaucher disease
WO2017012711A1 (fr) * 2015-07-19 2017-01-26 Tracey Lennemann Nouvelle utilisation d'acide hyaluronique
US10449214B2 (en) 2015-07-19 2019-10-22 Tracey Lennemann Use of hyaluronic acid

Also Published As

Publication number Publication date
EP0910389A4 (fr) 2001-09-19
CN1212628A (zh) 1999-03-31
JP2002504083A (ja) 2002-02-05
EP0910389A1 (fr) 1999-04-28
CN1149088C (zh) 2004-05-12

Similar Documents

Publication Publication Date Title
AU729086C (en) Method of promoting bone growth with hyaluronic acid and growth factors
US6221854B1 (en) Method of promoting bone growth with hyaluronic acid and growth factors
EP0910389A1 (fr) Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance
DE60132343T2 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
Hildebrand et al. The effects of platelet-derived growth factor-BB on healing of the rabbit medial collateral ligament
Batten et al. Influence of dosage and timing of application of platelet‐derived growth factor on early healing of the rat medial collateral ligament
AU647905B2 (en) Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention
US5885960A (en) Method of treatment comprising administering a combination comprising FGF and polyelectrolytes
AU629443B2 (en) Composition and method for the treatment of osteoporosis in mammals
EP1220693B1 (fr) Formulations destinees a l'administration de proteines osteogeniques
CZ102498A3 (cs) Gelový farmaceutický prostředek obsahující růstový faktor
US6472379B1 (en) Angiogenesis inhibition
CA2246747C (fr) Procede favorisant la croissance osseuse a l'aide d'acide hyaluronique et de facteurs de croissance
US20110207666A1 (en) Method of promoting bone growth with hyaluronic acid and growth factors
AU2005200146B2 (en) Method of promoting bone growth with hyaluronic acid and growth factors
CN109562124A (zh) 用于处理肌腱退化的方法和组合物
EP1475109A1 (fr) Formulations destinées a l'administration de protéines osteogéniques
Gillingham et al. ACUTE IGF-I TREATMENT FACILITATES TRANSITION FROM PARENTERAL TO ENTERAL NUTRITION IN RATS WITH SHORT BOWEL SYNDROME
JP2002507193A (ja) Ｉｇｆ−ｉ応答性の状態についての治療のための組成物および方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192822.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 331238

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2246747

Country of ref document: CA

Ref document number: 2246747

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997916976

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997916976

Country of ref document: EP